Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
- Resource Type
- Article
- Source
- The Lancet; November 2023, Vol. 402 Issue: 10415 p1835-1847, 13p
- Subject
- Language
- ISSN
- 01406736; 1474547X